Page last updated: 2024-08-05 11:20:16
isoflavones
Any isoflavonoid with a 3-aryl-1-benzopyran-4-one (3-aryl-4H-chromen-4-one) skeleton and its substituted derivatives.
ChEBI ID: 38757
Members (11)
| Member | Definition | Role |
|---|
| 3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one | | 3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one |
| 4-methyl-2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentanoic acid [3-(4-nitrophenyl)-4-oxo-1-benzopyran-7-yl] ester | | 4-methyl-2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentanoic acid [3-(4-nitrophenyl)-4-oxo-1-benzopyran-7-yl] ester |
| 4',7,8-trihydroxyisoflavone | | 8-Hydroxydaidzein |
| 7-Acetoxy-2-methylisoflavone | | 7-Acetoxy-2-methylisoflavone |
| 7-Hydroxy-2-methylisoflavone | | 7-Hydroxy-2-methylisoflavone |
| 7-hydroxy-8-(4-morpholinylmethyl)-3-phenyl-1-benzopyran-4-one | | 7-hydroxy-8-(4-morpholinylmethyl)-3-phenyl-1-benzopyran-4-one |
| 8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxy-1-benzopyran-4-one | | 8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxy-1-benzopyran-4-one |
| acetic acid (4-oxo-3-phenyl-1-benzopyran-7-yl) ester | | acetic acid (4-oxo-3-phenyl-1-benzopyran-7-yl) ester |
| ipriflavone | A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. | ipriflavone |
| isoflavone | A simplest member of the class of isoflavones that is 4H-chromen-4-one in which the hydrogen at position 3 is replaced by a phenyl group. | isoflavone |
| lupiwighteone | | Lupiwighteone |
Research
Studies (297)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|
| pre-1990 | 20 (6.73) | 18.7374 |
| 1990's | 119 (40.07) | 18.2507 |
| 2000's | 59 (19.87) | 29.6817 |
| 2010's | 72 (24.24) | 24.3611 |
| 2020's | 27 (9.09) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|
| Trials | 47 (13.06%) | 5.53% |
| Reviews | 31 (8.61%) | 6.00% |
| Case Studies | 4 (1.11%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 278 (77.22%) | 84.16% |